A panel of experts in the management of diabetes addresses the profound burden of type 1 diabetes (T1D), emphasizing heightened familial predisposition for this condition. They explore geographic disparities as well as the role of prediabetes in this patient population.
Kashif Latif, MD defines diabetes, shedding light on the pivotal role of B cells. He introduces the concept of diabetes stages and emphasizes the critical importance of early intervention to prevent complications.
Kent Stoneking Pharm D, CDECS, shares his personal T1D story and underscores the critical importance of early diagnosis and intervention for this condition. Following his story, Marianne Briggs, DNP, FNP-C, provides invaluable suggestions for identifying individuals at risk for T1D through effective screening methods.
Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, discusses the stages of T1D progression. She emphasizes the risks of delaying intervention in stage 2 T1D, including heightened DKA risk and severe complications, along with potential treatment efficacy reduction and poorer long-term glycemic control.
Dr Jennifer D. Goldman and Marianne Briggs, DNP, FNP-C explore the critical role of antibodies in determining T1D progression and emphasize the importance of regular screening. In this segment learn about the four main antibodies pivotal in T1D screening and stage progression.
In this discussion, a panel of diabetes management experts examines the groundbreaking potential of teplizumab, the first FDA-approved therapy of its kind, in delaying the onset of T1D stage progression. They discuss its unique mechanism of action and explore its pivotal role in early intervention strategies.
Kent Stoneking Pharm D, CDECS and Marianne Briggs, DNP, FNP-C share their experiences with the dosing regimen and infusion process for teplizumab. This segment offers an in-depth look at the 14-day course of treatment, providing insights into the patient experience and what individuals can expect during this crucial intervention period.
A panel of experts in the management of diabetes share their key takeaways and clinical pearls for the utilization of teplizumab for the delay of onset of type 1 diabetes.
